Medical device cybersecurity hinges on software supply chain governance

At a glance

What this is: This is a medical device cybersecurity compliance guide focused on seven steps, with SBOM transparency, vulnerability detection, license monitoring, and SDLC monitoring as the central controls.

Why it matters: It matters to security and identity practitioners because device software governance now intersects with supply chain risk, compliance evidence, and access to regulated environments where lifecycle control and accountability are mandatory.

👉 Read Kusari's guide on medical device cybersecurity and FDA 524B compliance

Context

Medical device cybersecurity is fundamentally a software supply chain problem once open source components are embedded in regulated products. The challenge is not only discovering what is in the device, but proving that the organisation can track, assess, patch, and document that software over the full lifecycle.

That makes the governance model familiar to identity practitioners even when the subject is not IAM: who owns the component inventory, who can approve changes, and who is accountable when a vulnerability or licensing issue appears. In regulated environments, weak lifecycle control becomes a compliance and safety issue, not just a technical defect.

Key questions

Q: How should medical device teams govern open source components across the product lifecycle?

A: They should treat each component as a governed asset with ownership, approval history, version tracking, and retirement criteria. That means tying the SBOM to release management, vulnerability response, and compliance records so the organisation can show what it shipped, what changed, and who accepted the risk at each stage.

Q: What breaks when SBOM data is incomplete in regulated devices?

A: Incomplete SBOM data breaks vulnerability assessment, patch prioritisation, and audit defensibility. If teams cannot see transitive dependencies or version drift, they cannot reliably judge exposure, prove due diligence, or explain why a device remains in service after a disclosure.

Q: Why do medical devices need continuous cybersecurity monitoring after launch?

A: Because new vulnerabilities, dependency changes, and license issues appear after deployment, while the device may stay in the field for years. Monitoring keeps security and compliance evidence current, which is essential when postmarket obligations require remediation rather than a one-time design review.

Q: Who is accountable when a regulated product ships with weak security controls?

A: Accountability follows the role that places the product on the market, which can include manufacturers, importers, or distributors depending on the situation. Rebranding can shift legal responsibility downstream, so organisations should not assume vendor labels alone determine who answers to regulators.

Technical breakdown

SBOM transparency and component provenance

A software bill of materials, or SBOM, is the inventory that identifies the components, versions, and dependencies inside a medical device. In regulated device environments, an SBOM is only useful when it is complete, current, and tied to change control, because hidden libraries and transitive dependencies often carry the risk. Provenance matters as much as detection, since teams need to know where a component came from and whether it has been reviewed for safety, licensing, and security impact.

Practical implication: establish an authoritative component inventory and require SBOM updates as part of every build and release decision.

Vulnerability management across the device lifecycle

Medical device vulnerability management is not a one-time scan but a lifecycle process that spans development, pre-market review, postmarket monitoring, and remediation. The practical problem is that a device can remain in service long after a vulnerability is disclosed, which means patching and compensating controls must be planned for both legacy and newly deployed units. Security teams need a workflow that maps findings to risk, remediation priority, and regulatory evidence.

Practical implication: connect vulnerability detection to a documented triage and remediation path that survives the device's operational life.

Continuous SDLC monitoring for regulated submissions

Continuous SDLC monitoring means security and compliance checks are embedded into the development pipeline rather than added at the end. For medical devices, that includes verifying the source, testing dependency changes, monitoring license obligations, and preserving evidence that the product was developed with secure-by-design controls. This matters because pre-market and postmarket obligations both depend on being able to show that security was not treated as an afterthought.

Practical implication: build release gates that capture security, quality, and compliance evidence before a device reaches submission or deployment.

NHI Mgmt Group analysis

SBOM governance is now a compliance control, not a documentation exercise. Once medical devices rely on open source software, the inventory of embedded components becomes part of the control environment. If teams cannot prove what is inside the product, they cannot consistently prove whether a vulnerability or license issue has been contained. Practitioners should treat SBOM quality as evidence of governance maturity, not as a static artefact.

Medical device risk increasingly looks like lifecycle identity and access governance for software components. The article's core logic is about ownership, traceability, and accountability across time, which mirrors the discipline behind identity lifecycle control. In practice, the question is not only whether a component exists, but who can change it, approve it, and retire it when risk changes. Teams should align software component governance with the same rigor used for privileged access and offboarding.

FDA 524B and the EU CRA push device teams toward evidence-ready security operations. These regulatory regimes require more than secure design claims. They demand traceability, vulnerability handling, and update discipline that can be demonstrated under review. That means compliance teams, product security teams, and engineering leads need shared controls and shared records, or the organisation will struggle to defend its posture during audit or incident review.

Continuous monitoring closes the gap between build-time confidence and field reality. Device security weakens when teams assume the pre-market review is enough. Vulnerabilities, dependency changes, and licensing issues all emerge after deployment, so operational monitoring must be part of the security model from the start. Practitioners should build processes that keep the device current in evidence as well as in code.

What this signals

Component governance will increasingly be measured by evidence quality, not policy language. Device teams that cannot show complete component provenance, vulnerability handling, and release traceability will struggle to defend their posture under regulatory scrutiny. The practical shift is toward operational records that prove control, not just statements that controls exist.

Software supply chain controls now sit closer to regulated identity governance than many medical teams recognise. The same discipline used for lifecycle ownership, approval boundaries, and revocation also applies to embedded software components and their change history. For practitioners, that means aligning engineering, security, and compliance around a shared evidence model rather than separate review processes.

For practitioners

• Create a governed SBOM source of truth Maintain a complete software bill of materials for each device build, including transitive dependencies, version history, and component ownership. Require change control updates whenever a component is added, replaced, or removed, so the SBOM remains audit-ready rather than archival.
• Tie vulnerability triage to device lifecycle status Map each disclosed vulnerability to the specific device model, software version, deployment stage, and compensating control. Use that mapping to prioritise remediation for products still in field use and to document why a patch, workaround, or update delay is acceptable.
• Embed license and compliance checks into the SDLC Scan dependencies for security defects and license obligations before release gates approve firmware or software builds. Preserve the results with build evidence so pre-market submissions and postmarket audits can show what was reviewed and when.
• Separate security ownership from code authorship Assign explicit accountability for third-party components, even when internal developers did not write the code. The responsible team should be able to answer who approved the component, who tracks its risk, and who can retire it if regulatory exposure changes.

Key takeaways

• Medical device cybersecurity is now inseparable from software supply chain governance and compliance evidence.
• SBOM accuracy, vulnerability handling, and SDLC monitoring are the controls that determine whether regulated devices can be defended under review.
• Teams that cannot prove component ownership and lifecycle traceability will struggle to manage both security exposure and regulatory accountability.

Key terms

• Software Bill of Materials: A software bill of materials is an inventory of the components and dependencies used in an application. It helps teams identify what they shipped, but it becomes most useful when paired with source verification, signature checks, and policy enforcement for third-party code.
• Postmarket Cybersecurity Surveillance: The process of monitoring devices after release for emerging vulnerabilities, adversary activity, and remediation needs. It is a governance mechanism that connects external threat intelligence, patch management, and operational ownership so that device security does not stop at product launch.
• Continuous SDLC Monitoring: Continuous SDLC monitoring is the practice of checking security, compliance, and quality controls throughout development rather than at release only. In regulated product environments, it creates evidence that dependencies, license obligations, and security findings were reviewed before shipment and not left to manual after-the-fact review.
• Lifecycle Cybersecurity: Lifecycle cybersecurity means security controls are maintained from design through deployment, maintenance, and retirement. For medical devices, it is the governance model that connects secure design, vulnerability response, update handling, and end-of-life decisions into one accountable process.

What's in the full article

Kusari's full guide covers the operational detail this post intentionally leaves for the source:

• Step-by-step SBOM generation workflow for regulated device builds and submissions
• Automated vulnerability detection and remediation workflow details for device software components
• License compliance monitoring approach for reducing operational and legal exposure
• Continuous SDLC monitoring checks that support pre-market and postmarket evidence

👉 The full Kusari guide covers SBOM generation, vulnerability detection, and lifecycle monitoring steps in more detail.

Deepen your knowledge

The NHI Foundation Level course, the industry's only accredited NHI security programme, covers NHI governance, machine identity security, and secrets management. It is designed for practitioners who need a stronger operating model for lifecycle control and accountability across modern security programmes.